Coronavirus: Immune Thrombocytopenic Purpura

Department of Health and Social Care written question – answered on 1st March 2022.

Alert me about debates like this

Photo of Christopher Chope Christopher Chope Conservative, Christchurch

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 December 21 to Question 86034 on Coronavirus: Immune Thrombocytopenic Purpura, what steps his department is taking to investigate the 427 suspected cases of major thromboembolic events with concurrent thrombocytopenia; and if the Government will make it its policy to those affected by those suspected cases of the availability of the Vaccine Damage Payment Scheme.

Photo of Maria Caulfield Maria Caulfield The Parliamentary Under-Secretary for Health and Social Care

The Medicines and Healthcare products Regulatory Agency (MHRA) has reviewed each Yellow Card report of suspected events of thrombosis with thrombocytopenia syndrome (TTS). All reports are followed up for further details of the event to allow a robust assessment. Following a scientific assessment of all the available data and a review by the Commission on Human MedicinesCOVID-19 Vaccines Benefit Risk Expert Working Group, it was determined that an association between the AstraZeneca COVID-19 vaccine and TTS was likely. As a result, the vaccine product information was updated to make the public and healthcare professionals aware of this adverse event and provide advice on the signs, symptoms and actions to be taken in a TTS event. All suspected reports of TTS continue to be monitored and the MHRA will take further regulatory actions and inform patients and prescribers if new evidence emerges.

All Vaccine Damage Payment Scheme claims are clinically assessed on a case-by-case basis by a third party, seeking further medical expertise as required.

Does this answer the above question?

Yes1 person thinks so

No5 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.